OBJECTIVE: We evaluated the prognostic value of the preoperative serum carcinoembryonic antigen (CEA) level in patients with colon cancer. METHODS: We reviewed 474 patients who underwent potentially curative resection for nonmetastatic colon cancer. Patients were categorized into two groups according to the preoperative serum CEA level: low CEA (<5 ng/ml) and high CEA (>or=5 ng/ml) groups. RESULTS: During the median 45-month follow-up period, the 5-year overall and disease-free survival rates for patients with a low CEA level were 81.7% and 82.4%, respectively, which were significantly higher than the rates for those with a high CEA level (69.9%; P = 0.011 and 70.6%; P = 0.002, respectively). A multivariate analysis revealed that a preoperative serum CEA level was a significant independent prognostic factor for both overall survival (P = 0.021) and disease-free survival (P = 0.026). Both the overall and disease-free survival rates in patients with stage II tumors differed significantly between the low and high CEA groups, whereas the rates did not different between those with stage I and III tumors. CONCLUSIONS: Preoperative serum CEA is a reliable predictor of recurrence and survival after curative surgery in patients with colon cancer, particularly in those classified as having stage II disease. (c) 2010 Wiley-Liss, Inc.
OBJECTIVE: We evaluated the prognostic value of the preoperative serum carcinoembryonic antigen (CEA) level in patients with colon cancer. METHODS: We reviewed 474 patients who underwent potentially curative resection for nonmetastatic colon cancer. Patients were categorized into two groups according to the preoperative serum CEA level: low CEA (<5 ng/ml) and high CEA (>or=5 ng/ml) groups. RESULTS: During the median 45-month follow-up period, the 5-year overall and disease-free survival rates for patients with a low CEA level were 81.7% and 82.4%, respectively, which were significantly higher than the rates for those with a high CEA level (69.9%; P = 0.011 and 70.6%; P = 0.002, respectively). A multivariate analysis revealed that a preoperative serum CEA level was a significant independent prognostic factor for both overall survival (P = 0.021) and disease-free survival (P = 0.026). Both the overall and disease-free survival rates in patients with stage II tumors differed significantly between the low and high CEA groups, whereas the rates did not different between those with stage I and III tumors. CONCLUSIONS: Preoperative serum CEA is a reliable predictor of recurrence and survival after curative surgery in patients with colon cancer, particularly in those classified as having stage II disease. (c) 2010 Wiley-Liss, Inc.
Authors: Soo Young Lee; Jeong Seon Jo; Hun Jin Kim; Chang Hyun Kim; Jae-Kyun Ju; Young Jin Kim; Hyeong Rok Kim Journal: Int J Colorectal Dis Date: 2014-11-01 Impact factor: 2.571
Authors: Giovanni Li Destri; Antonio Salvatore Rubino; Rosalia Latino; Fabio Giannone; Raffaele Lanteri; Beniamino Scilletta; Antonio Di Cataldo Journal: Int Surg Date: 2015-04
Authors: Ondrej Fiala; Jindrich Finek; Tomas Buchler; Vit Martin Matejka; Lubos Holubec; Jana Kulhankova; Zbynek Bortlicek; Vaclav Liska; Ondrej Topolcan Journal: Target Oncol Date: 2015-12 Impact factor: 4.493